Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer

NEXT STORY
ERYTECH Announces a Poster Presentation for TRYbeCA1 at the ASCO 2020
PREV STORY
The lancets market is projected to reach USD 1,442 million by 2024 from USD 804 million in 2019, at a CAGR of 12.4%
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer

NEXT STORY
ERYTECH Announces a Poster Presentation for TRYbeCA1 at the ASCO 2020
PREV STORY
The lancets market is projected to reach USD 1,442 million by 2024 from USD 804 million in 2019, at a CAGR of 12.4%
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

OncoMed Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference

REDWOOD CITY, Calif., Nov. 22, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a ...

author_avatar
NASDAQ Market News

Celsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer Association’s 12th Annual Scientific Meeting

LAWRENCEVILLE, N.J., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation today announced that an ...

author_avatar
NASDAQ Market News

Matinas BioPharma Commences Patient Dosing in NIH-Sponsored Phase 2a Study with Lead Anti-Infective Candidate MAT2203

– Phase 2a study of MAT2203 for the treatment of mucocutaneous candidiasis infections; Topline ...

author_avatar
NASDAQ Market News